April 29, 2025
“THIS IS THE BEGINNING OF A NEW CHAPTER”
BIOSTOCK HAS INTERVIEWED ISOFOL’S CEO
April 28, 2025
ISOFOL INCLUDES FIRST PATIENT IN A CLINICAL
PHASE Ib/II STUDY OF ARFOLITIXORIN
About Isofol
Isofol Medical AB (publ) is a research-based biotechnology company working to improve the prognosis for patients with severe forms of cancer. The company’s drug candidate arfolitixorin aims to increase the effect of first-line standard treatment for several forms of solid tumors and is currently being studied in colorectal cancer, the world’s third most common cancer, where the medical need for better treatments is urgent. A phase Ib/II study is now being conducted with a new dosing regimen that is expected to optimize the effect of the drug candidate. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.
Upcoming Events
- May 13, 2025 - May 16, 2025
CEO interview in connection with the announcement of the rights issue
In connection with Isofol's decision to new rights issue, CEO Petter Segelman Lindqvist will make a CEO speech that will be published on the website on Tuesday. - May 20, 2025 - May 21, 2025
The Global Forum 2025, Sweden
Isofol is participating in the Global Forum 2025 in Lund, which is organized by BioStock. On May 20 at 4:00 PM, CEO Petter Segelman Lindqvist will present the company. - May 21, 2025 - May 21, 2025
Interim report January-March 2025
Media – Lates pressreleases
Notice to attend the Extraordinary General Meeting held on June 11, 2025 in Isofol Medical AB (publ)
GOTHENBURG, Sweden, May 12, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites the shareholders of Isofol Medical AB (publ), Reg. No….
The Board of Directors of Isofol resolves on a fully guaranteed Rights Issue of units amounting to approximately SEK 85 million and proposes an over-allotment issue of approximately SEK 10 million
GOTHENBURG, Sweden, 12 May 2025 – The Board of Directors of Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol” or the “Company”) has today…
Isofol includes first patient in a clinical phase Ib/II study of arfolitixorin
GOTHENBURG, Sweden, April 28, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces that the first patient has been included in the clinical…
INVESTORS – latest reports and presentations
FOLLOW US
Stay updated on the latest news by
following Isofol on Linkedin.
